PATADAY TWICE DAILY RELIEF
Clinical safety rating
cautionComprehensive clinical and safety monograph for PATADAY TWICE DAILY RELIEF (PATADAY TWICE DAILY RELIEF).
Pataday (olopatadine) is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits the release of histamine and other inflammatory mediators from mast cells, reducing allergic conjunctivitis symptoms.
| Metabolism | Olopatadine undergoes minimal hepatic metabolism. Systemic absorption is low after ocular administration; the small absorbed fraction is metabolized by CYP3A4 and other CYP450 enzymes. |
| Excretion | Olopatadine is predominantly eliminated via renal excretion, with approximately 60-70% of the dose recovered as unchanged drug in urine. The remaining 30-40% is eliminated as metabolites (including N-demethylated and N-oxide derivatives) primarily via urine, with minor fecal excretion (<5%). |
| Half-life | The terminal elimination half-life of olopatadine is approximately 8-12 hours in healthy adults, supporting twice-daily dosing for sustained therapeutic effect. |
| Protein binding | Olopatadine is approximately 55% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution (Vd) of olopatadine is approximately 1.3 L/kg, indicating extensive distribution into tissues beyond plasma volume. |
| Bioavailability | Bioavailability via ocular route: Systemic absorption is minimal; however, following topical ocular administration, the systemic bioavailability is approximately 0.5-1% due to low absorption through the conjunctiva and nasolacrimal duct. |
| Onset of Action | Ocular administration: Onset of action occurs within 30 minutes, with peak effect observed at 2 hours post-dose. |
| Duration of Action | Duration of action is approximately 8-12 hours following a single ocular dose. Twice daily dosing maintains symptom relief over 24 hours. |
| Molecular Weight | 373.88 |
1 drop in each affected eye twice daily (approximately every 6-8 hours)
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for any degree of renal impairment. No specific GFR-based recommendations provided by manufacturer. |
| Liver impairment | No dosage adjustment required for any degree of hepatic impairment. No specific Child-Pugh based recommendations provided by manufacturer. |
| Pediatric use | Children 2 years and older: 1 drop in each affected eye twice daily. Safety and efficacy in children under 2 years have not been established. |
| Geriatric use | No specific dosage adjustment required; geriatric patients should use the same dose as younger adults. Elderly may be more susceptible to local adverse effects; monitor for excessive tearing, conjunctival irritation, or dry eye symptoms. |
| 1st trimester | No adequate studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. |
| 2nd trimester | No adequate studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. |
| 3rd trimester | No adequate studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. |
Clinical note
Comprehensive clinical and safety monograph for PATADAY TWICE DAILY RELIEF (PATADAY TWICE DAILY RELIEF).
| Placental transfer | Not studied; low systemic absorption with topical ocular use suggests minimal placental transfer. |
| Breastfeeding | Olopatadine is excreted in human milk following oral administration; however, topical ocular use likely results in negligible systemic exposure. Caution is advised when administered to a nursing woman. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No evidence of human teratogenicity. Animal studies show no malformations at clinically relevant doses. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required. Routine obstetric care. |
| Fertility Effects | No human data. Animal studies show no impairment of fertility. |
■ FDA Black Box Warning
None
| Common Effects | Eye pain Eye irritation Abnormal eye sensation Eye discomfort Sleepiness Weakness Dryness in mouth |
| Serious Effects |
Hypersensitivity to olopatadine or any component of the formulationPrimary angle-closure glaucoma (relative, but absolute if untreated)
| Precautions | Not for injection, Patients should not wear contact lenses if eyes are red, May cause transient burning or stinging, Contains benzalkonium chloride which may be absorbed by soft contact lenses |
| Food/Dietary | No known food interactions. Avoid rubbing eyes which may worsen symptoms. |
| Clinical Pearls | Pataday Twice Daily Relief contains olopatadine 0.1%, an ophthalmic mast cell stabilizer and antihistamine. Use for prevention of ocular itching in allergic conjunctivitis. Advise patients to wait 10 minutes after administration before inserting contact lenses. Monitor for transient stinging or blurred vision. Not for treatment of contact lens-related irritation. |
| Patient Advice | Use exactly as prescribed: one drop in each affected eye twice daily (every 6-8 hours). · Wash hands before instilling drops. Do not touch the dropper tip to any surface. · Remove contact lenses before use; wait at least 10 minutes before reinserting. · Do not use if solution changes color or becomes cloudy. · Common side effects include mild stinging or burning upon instillation, which usually resolves. · Avoid driving or operating machinery immediately after use if vision is blurred. |
Loading safety data…